Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in caucasian patients

Oncology Letters

Volumn 1, Issue 4, 2010, Pages 729-732

  Kollermann J ^a   Albrecht, H ^b   Schlomm, T ^c   Huland, H ^c   Graefen, M ^c   Bokemeyer, C ^b   Simon, R ^a   Sauter, G ^a   Wilczak, W ^a  

^a Eltville/Rhein Hamburg   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Martini Klinik   (Germany)

Author keywords

Androgen resistance; BRAF; Prostate cancer

Indexed keywords

B RAF KINASE;

ARTICLE; CAUCASIAN; ENZYME ACTIVATION; EXON; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PROSTATE CANCER;

EID: 77954948708     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000127     Document Type: Article

References (22)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 1: 10-30, 2005.
2. Cohen Y, Xing M, Mambo E, et al: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 8: 625-627, 2003.
3. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 19: 7099-7109, 2004.
4. Preto A, Goncalves J, Rebocho A P, et al: Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer 1: 387, 2009.
5. Cho NY, Choi M, Kim BH, Cho YM, Moon KC and Kang GH: BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 8: 1858-1862, 2006.
6. Chong H, Vikis HG and Guan KL: Mechanisms of regulating the Raf kinase family. Cell Signal 5: 463-469, 2003.
7. Davies H, Dicks E, Stephens P, et al: High throughput DNA sequence variant detection by conformation sensitive capillary electrophoresis and automated peak comparison. Genomics 3: 427-432, 2006.
8. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 7: 1454-1457, 2003.
9. Honecker F, Wermann H, Mayer F, et al: Microsatellite instability, mismatch repair defciency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 13: 2129-2136, 2009.
10. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR and Wooster R: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91: 355-358, 2004.
11. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867, 2004.
12. Hoefich KP, Gray DC, Eby MT, et al: Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2: 999-1006, 2006.
13. Sumimoto H, Miyagishi M, Miyoshi H, et al: Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 36: 6031-6039, 2004.
14. Pratilas CA and Solit DB: Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials 2: 121-134, 2007.
15. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM and Abate-Shen C: Combinatorial activities of Akt and B-Raf/ Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 39: 14477-14482, 2006.
16. Jeong JH, Wang Z, Guimaraes AS, et al: BRAF activation initiates but does not maintain invasive prostate adenocarci-noma. PLoS One 12: e3949, 2008.
17. Liu T, Willmore-Payne C, Layfeld LJ and Holden JA: Lack of BRAF activating mutations in prostate adenocarcinoma: a study of 93 cases. Appl Immunohistochem Mol Morphol 2: 121-125, 2009.
18. Riely GJ, Politi KA, Miller VA and Pao W: Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 24: 7232-7241, 2006.
19. Al-Kuraya K, Schraml P, Sheikh S, et al: Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol 7: 891-897, 2005.
20. Choi DH, Shin DB, Lee MH, et al: A comparison of fve immu-nohistochemical biomarkers and HER-2/neu gene amplifcation by fuorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 8: 1587-1595, 2003.
21. Michaloglou C, Vredeveld LC, Mooi WJ and Peeper DS: BRAF(E600) in benign and malignant human tumours. Oncogene 7: 877-895, 2008.
22. Marchetti A, Felicioni L and Buttitta F: Assessing EGFR mutations. N Engl J Med 5: 526-528, 2006.